Literature DB >> 14686224

Fluconazole- and levofloxacin-induced torsades de pointes in an intensive care unit patient.

Pritesh J Gandhi1, Pearl A Menezes, Hien T Vu, Amy L Rivera, Karthik Ramaswamy.   

Abstract

Patients initiated on fluconazole and levofloxacin should be closely monitored for QTc-interval prolongation. While there have been published reports of fluconazole and levofloxacin causing QTc-interval prolongation when given alone, coadministration of these two agents may further increase this risk. This case describes an episode of TdP in which levofloxacin and fluconazole were likely significant factors. QT prolongation was present at baseline prior to drug initiation (QTc = 454-505 ms) and levofloxacin resulted in further prolongation (QTc = 480-536 ms). After two days of therapy with fluconazole, overlapping with levofloxacin, the patient had an episode of PMVT with syncope, and progressive QT prolongation was evident (QTc = 554 ms). Only mild hypokalemia (potassium concentration = 3.6 meq/L) was present, and not additional etiologies for TdP were identified. Levofloxacin and fluconazole were discontinued and no further PMVT was observed, but the QT interval did not return to normal until after an additional 11 days (QTc = 436 ms). As in many cases of TdP, multiple factors were involved. Renal failure, drug dosing, mild hypokalemia, and a baseline abnormal QT interval potentiated the role of levofloxacin and fluconazole in the development of TdP. We recommend that neither drug be used alone or in combination when there is baseline QT prolongation. We also recommend that concomitant use of these agents be avoided when possible. If combination therapy is required, caution is warranted, particularly in patients with risk factors for QT prolongation. Specific attention should be given to drug dosing, interactions, electrolytes, and ECG monitoring.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14686224     DOI: 10.1093/ajhp/60.23.2479

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  11 in total

1.  Prevalence of potential drug-drug interactions in bone marrow transplant patients.

Authors:  Rosimeire Barbosa Fonseca Guastaldi; Adriano Max Moreira Reis; Albert Figueras; Silvia Regina Secoli
Journal:  Int J Clin Pharm       Date:  2011-10-13

2.  Analysis of Respiratory Fluoroquinolones and the Risk of Sudden Cardiac Death Among Patients Receiving Hemodialysis.

Authors:  Magdalene M Assimon; Patrick H Pun; Lily Chin-Hua Wang; Sana M Al-Khatib; M Alan Brookhart; David J Weber; Wolfgang C Winkelmayer; Jennifer E Flythe
Journal:  JAMA Cardiol       Date:  2022-01-01       Impact factor: 30.154

Review 3.  Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period.

Authors:  Emanuel Raschi; Elisabetta Poluzzi; Chiara Zuliani; Arno Muller; Herman Goossens; Fabrizio De Ponti
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

Review 4.  Cardiac risks associated with antibiotics: azithromycin and levofloxacin.

Authors:  Zhiqiang Kevin Lu; Jing Yuan; Minghui Li; S Scott Sutton; Gowtham A Rao; Sony Jacob; Charles L Bennett
Journal:  Expert Opin Drug Saf       Date:  2014-12-10       Impact factor: 4.250

Review 5.  QT prolongation with antimicrobial agents: understanding the significance.

Authors:  Robert C Owens
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin.

Authors:  Ari J Alexandrou; Rona S Duncan; Anneli Sullivan; Jules C Hancox; Derek J Leishman; Harry J Witchel; Joanne L Leaney
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

7.  Torsades de Pointes ventricular tachycardia in a pediatric patient treated with fluconazole.

Authors:  Jesse J Esch; Michal J Kantoch
Journal:  Pediatr Cardiol       Date:  2007-09-12       Impact factor: 1.655

8.  Analysis of Relationship between Levofloxacin and Corrected QT Prolongation Using a Clinical Data Warehouse.

Authors:  Man Young Park; Eun Yeob Kim; Young Ho Lee; Woojae Kim; Ku Sang Kim; Seung Soo Sheen; Hong Seok Lim; Rae Woong Park
Journal:  Healthc Inform Res       Date:  2011-03-31

9.  Association of oral ciprofloxacin, levofloxacin, ofloxacin and moxifloxacin with the risk of serious ventricular arrhythmia: a nationwide cohort study in Korea.

Authors:  Yongil Cho; Hyun Soo Park
Journal:  BMJ Open       Date:  2018-09-28       Impact factor: 2.692

10.  Skin and skin structure infections: treatment with newer generation fluoroquinolones.

Authors:  Philip Giordano; Kurt Weber; Gail Gesin; Jason Kubert
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.